Brequinar

Edit links
Source: Wikipedia, the free encyclopedia.
Brequinar
Clinical data
Trade namesBrequinar
Identifiers
  • 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid
JSmol)
  • CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O
  • InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
  • Key:PHEZJEYUWHETKO-UHFFFAOYSA-N

Brequinar (DuP-785) is a drug that acts as a potent and selective inhibitor of the enzyme dihydroorotate dehydrogenase. It blocks synthesis of pyrimidine based nucleotides in the body and so inhibits cell growth. Brequinar was invented by DuPont Pharmaceuticals in the 1980s.[1] In 2001, Bristol-Myers Squibb acquired DuPont, and in 2017, Clear Creek Bio acquired the rights to brequinar from BMS.[2]

Brequinar has been investigated as an

antiviral drug.[8][9][10] Clear Creek Bio is currently developing brequinar as a potential treatment for COVID-19.[11]

Inhibition of dihydroorotate dehydrogenase activity by brequinar may represent an efficient approach to the elimination of undifferentiated cells for safe

PSC‐derived differentiated cells based therapies.[12]

See also

References

  1. PMID 4053030
    .
  2. ^ "Bristol Myers Squibb Company History Timeline". May 3, 2022.
  3. S2CID 28974570
    .
  4. PMID 30663496
    .
  5. PMID 21861807
    .
  6. S2CID 53036782
    .
  7. PMID 31557612
    .
  8. PMID 31146110
    .
  9. PMID 31635418
    .
  10. PMID 31941776
    .
  11. ^ "Clear Creek Bio Doses First Patient in Phase 2 Outpatient Study of Brequinar to Treat COVID-19". November 20, 2020.
  12. S2CID 222280648
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Brequinar&oldid=1215461323"